New diabetes drug MK-1403 enters human testing

NCT ID NCT07242469

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This early-stage study tests an experimental drug called MK-1403 in people with type 2 diabetes. The main goals are to check if the drug is safe and tolerable, and to see how it behaves in the body. Researchers will also measure its effect on a marker of inflammation (hsCRP). About 52 participants will receive either MK-1403 or a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MK-1403 (an experimental oral drug)
What this could lead to
If successful, this could point toward a new treatment option for type 2 diabetes that also reduces inflammation.
What could go wrong
This is an early Phase 1 trial with only 52 participants, so it is primarily testing safety and dosing. The drug may not prove effective or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Advanced Pharma CR, LLC ( Site 0003)

    RECRUITING

    Miami, Florida, 33147, United States

  • Anaheim Clinical Trials ( Site 0006)

    RECRUITING

    Anaheim, California, 92801, United States

  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0005)

    COMPLETED

    Springfield, Missouri, 65802, United States

  • ProSciento Inc. ( Site 0001)

    RECRUITING

    Chula Vista, California, 91911, United States

  • QPS-MRA, LLC ( Site 0004)

    RECRUITING

    South Miami, Florida, 33143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.